3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.
By TheStreet Wire ,

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 86 points (0.5%) at 17,915 as of Tuesday, Nov. 3, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,603 issues advancing vs. 1,362 declining with 155 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include

AMAG Pharmaceuticals

(

AMAG

), down 19.8%,

Incyte

(

INCY

), down 2.6%,

GlaxoSmithKline

(

GSK

), down 1.6%,

Biomarin Pharmaceutical

(

BMRN

), down 1.3% and

AbbVie

(

ABBV

), down 1.1%. Top gainers within the industry include

Mylan

(

MYL

), up 3.5%,

Perrigo

(

PRGO

), up 1.7% and

Novo Nordisk A/S

(

NVO

), up 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Regeneron Pharmaceuticals

(

REGN

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Regeneron Pharmaceuticals is down $5.78 (-1.0%) to $573.22 on average volume. Thus far, 423,041 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 914,100 shares. The stock has ranged in price between $564.50-$581.00 after having opened the day at $581.00 as compared to the previous trading day's close of $579.00.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $56.7 billion and is part of the health care sector. Shares are up 41.1% year-to-date as of the close of trading on Monday. Currently there are 8 analysts that rate Regeneron Pharmaceuticals a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Regeneron Pharmaceuticals

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Regeneron Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Pfizer

(

PFE

) is down $0.24 (-0.7%) to $34.82 on average volume. Thus far, 10.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 28.2 million shares. The stock has ranged in price between $34.65-$35.01 after having opened the day at $34.99 as compared to the previous trading day's close of $35.06.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $208.6 billion and is part of the health care sector. Shares are up 12.6% year-to-date as of the close of trading on Monday. Currently there are 9 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Pfizer Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is down $0.60 (-0.6%) to $109.00 on light volume. Thus far, 2.6 million shares of Gilead exchanged hands as compared to its average daily volume of 11.9 million shares. The stock has ranged in price between $108.32-$109.54 after having opened the day at $109.40 as compared to the previous trading day's close of $109.60.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $158.7 billion and is part of the health care sector. Shares are up 16.3% year-to-date as of the close of trading on Monday. Currently there are 11 analysts that rate Gilead a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...